Core Viewpoint - Halper Sadeh LLC is investigating whether Enhabit, Inc. is obtaining a fair price for its shareholders in the proposed sale to Kinderhook Industries, LLC for $13.80 per share in cash [1] Group 1: Investigation Details - The investigation focuses on potential violations of federal securities laws and breaches of fiduciary duties by Enhabit and its board of directors [1] - Key concerns include whether the company obtained the best possible price for shareholders, conducted a fair sales process free of conflicts of interest, and disclosed all material information necessary for shareholders to evaluate the transaction [1] Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to seek increased consideration, additional disclosures, or other relief for shareholders [1] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [1]

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. and its executives, alleging that they concealed significant issues in the company's transition to a Software-as-a-Service (SaaS) model while publicly promoting its success [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Varonis executives misrepresented the company's ability to convert existing customers to the SaaS model, stating they were "well on our way" to a successful transition, while the reality showed a struggling renewal cycle in the Federal vertical and legacy on-premises business [2][5][9]. - Following a disclosure on October 28, 2025, that revealed a 63.9% year-over-year decline in term license revenue and a reduced Annual Recurring Revenue (ARR) outlook, Varonis experienced a 48% drop in stock price, losing approximately $3.8 billion in market value in a single day [3][9]. Group 2: Financial Performance and Guidance - The company faced a performance miss attributed to weaker renewals in its Federal vertical and non-Federal on-prem subscription business, contradicting previous optimistic statements about growth [9]. - After the Q3 performance miss, Varonis significantly reduced its Q4 revenue and full-year ARR guidance, indicating a more challenging outlook than previously communicated [9]. Group 3: Legal Proceedings and Investor Actions - The lead plaintiff deadline for the ongoing lawsuit is set for March 9, 2026, and investors who suffered losses during the class period from February 4, 2025, to October 28, 2025, are encouraged to participate [1][7][8]. - Hagens Berman, the law firm handling the case, is actively advising affected investors and has a history of successful litigation in securities fraud cases [6][11].

Core Viewpoint - Johnson Fistel, PLLP is investigating Commvault Systems, Inc. for potential compliance issues with federal securities laws following significant investor losses after the company's recent earnings report [1][4]. Group 1: Financial Performance - Commvault reported a 40% growth in SaaS annual recurring revenue, amounting to $364 million for the third quarter of fiscal 2026 [3]. - This growth represents a deceleration from the 56% growth reported in the second quarter of fiscal 2026 [3]. Group 2: Stock Price Impact - Following the earnings report, Commvault's stock price fell by $40.23 per share, approximately 31.1%, closing at $89.13 per share [4]. - The decline in stock price resulted in significant losses for investors [4]. Group 3: Investigation Details - The investigation by Johnson Fistel focuses on whether Commvault and its executives complied with federal securities laws in light of the reported financial results and subsequent stock price decline [1][4].

Core Viewpoint - A securities fraud lawsuit has been filed against Kyndryl Holdings, Inc. and certain executives following a significant drop in share price due to internal accounting issues and executive departures [1][2]. Group 1: Company Issues - Kyndryl Holdings' shares fell over 50% in intraday trading on February 9, 2026, after the company announced an internal accounting review and a delay in filing its quarterly report [2]. - The internal review focuses on cash management practices, related disclosures, and internal control over financial reporting, prompted by document requests from the SEC [2]. - Kyndryl does not expect a restatement of its financials but anticipates reporting material weaknesses in internal control over financial reporting for FY25 and the first three quarters of FY26 [2]. Group 2: Lawsuit Details - The lawsuit alleges that Kyndryl made false and misleading statements regarding its financial statements, internal controls, and the timely filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 [3]. - It is claimed that Kyndryl lacked adequate internal controls and materially understated issues related to them, leading to misleading statements about the company's business and prospects [3]. Group 3: Investor Information - Investors who purchased Kyndryl Holdings common stock between August 7, 2024, and February 9, 2026, may be eligible to participate in the lawsuit, regardless of whether they have sold their shares [4]. - The deadline to seek appointment as lead plaintiff is April 13, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Kyndryl Holdings are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - A class action lawsuit has been filed against Varonis Systems, Inc. for allegedly misleading investors regarding its ability to convert its customer base, leading to a significant decline in stock price after disappointing financial results were announced [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Varonis securities between February 4, 2025, and October 28, 2025 [1][2]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against Varonis - The lawsuit claims that Varonis and its executives raised investor expectations while knowing the company was not positioned to effectively convert existing users to its SaaS offerings, which impacted annual recurring revenue (ARR) growth potential [3]. - The company faced challenges with renewals and conversions in its subscription business, leading to a significant ARR miss and a reduction in guidance for the fiscal year 2025 [4]. Group 3: Financial Impact - Following the announcement of disappointing financial results on October 28, 2025, Varonis' stock price plummeted from $63.00 to $32.34 per share, a decline of over 48% in one day [5].

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on patients and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [3]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Points - The Corcept Therapeutics class action lawsuit seeks to represent investors who purchased common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that Corcept misrepresented the support for its relacorilant New Drug Application (NDA), suggesting it was close to FDA approval despite known concerns from the FDA regarding clinical evidence [1] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, leading to a more than 50% drop in the company's stock price [1] - The FDA's CRL indicated that the clinical studies submitted were insufficient to demonstrate relacorilant's efficacy, and the FDA had previously warned Corcept about significant review issues [1] Company Overview - Corcept Therapeutics is engaged in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a lead candidate for treating hypercortisolism [1] - The company has faced significant scrutiny regarding the adequacy of its clinical development program for relacorilant, which has implications for its future product approvals and market performance [1] Legal Context - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

Core Viewpoint - NuScale Power Corporation is facing a class action lawsuit due to alleged misleading statements regarding its commercialization partnership with ENTRA1 Energy LLC and significant financial losses related to this partnership [1][3][4]. Company Overview - NuScale Power Corporation specializes in small modular nuclear reactors, specifically the NuScale Power Module (NPM), aimed at generating energy within larger power plants [2]. - The company entered a global commercialization partnership with ENTRA1 Energy LLC, which was expected to advance its NPM technology from development to deployment [2]. Allegations of the Lawsuit - The lawsuit claims that NuScale and its executives made false statements about ENTRA1's capabilities, failing to disclose that ENTRA1 had no significant experience in building or operating nuclear power projects [3]. - It is alleged that NuScale's reliance on ENTRA1 exposed the company to undisclosed risks, including potential failures and regulatory challenges in its commercialization strategy [3]. Financial Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses, which surged over 3,000% to $519 million from $17 million in the previous year, primarily due to a $495 million payment to ENTRA1 [4]. - The company's quarterly net loss escalated to $532 million, up from $46 million in the prior year, following the announcement of the TVA agreement [4]. - Following these revelations, NuScale's Class A shares dropped more than 12% over a two-day trading period [4]. Legal Process - Investors who purchased NuScale Class A common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is representing the plaintiffs and is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading financial statements and inadequate internal controls during the specified class period [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Brander v. Kyndryl Holdings, Inc., and it allows purchasers of Kyndryl securities from August 7, 2024, to February 9, 2026, to seek lead plaintiff status by April 13, 2026 [1][5]. - The lawsuit alleges that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, which led to an inability to timely file its Quarterly Report for the quarter ended December 31, 2025 [3][4]. Financial and Operational Implications - On February 9, 2026, Kyndryl announced it would be unable to file its Quarterly Report on Form 10-Q on time, citing a review of its cash management practices and internal controls following SEC inquiries [4]. - The company anticipates reporting material weaknesses in its internal control over financial reporting for the fiscal year ended March 31, 2025, and the first two quarters of fiscal year 2026 [4]. - Following the announcement, Kyndryl's stock price fell by 55% [4]. Company Background - Kyndryl operates as a technology services company and IT infrastructure services provider [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6].

Core Viewpoint - Halper Sadeh LLC is investigating the sale of Arcellx, Inc. to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share based on certain milestones [1] Group 1: Investigation Details - The investigation focuses on whether Arcellx and its board violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [2] - Concerns include the fairness of the sales process and potential conflicts of interest, as well as the adequacy of disclosed material information for shareholders to evaluate the transaction [2] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [3] - The firm represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]